Twist Bioscience Corporation (TWST) has a MoatMap StockRank of 60/100 based on Quality (39/100), Value (36/100), and Momentum (68/100) factor scores. The current signal is HOLD. Twist Bioscience has a revolutionary silicon-based DNA synthesis platform, but it remains unprofitable with high cash burn, violating the Terry Smith quality filter of owning only established compounders.
Twist Bioscience Corporation is a leading synthetic biology company providing high-quality, custom DNA products for a wide range of applications, including drug discovery, diagnostics, and data storage. The company's proprietary silicon-based DNA writing platform enables the rapid, high-throughput, and cost-effective synthesis of DNA, offering a significant technological advantage over traditional methods. Its unique manufacturing process establishes a strong competitive moat in the synthetic biology market.
| Price | $69.90 |
| Market Cap | $4.3B |
| P/E (Forward) | -36.06 |
| Price/Book | 10.10 |
| Return on Equity | -18.2% |
| Return on Invested Capital | -24.8% |
| Debt/Equity | 24.36 |
| Gross Margin | 52.1% |
| Operating Margin | -34.9% |
| Revenue Growth | 19.3% |
| Free Cash Flow | $-58M |
Twist Bioscience Corporation operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).